Georgia Expands Medical Cannabis Access Under New Law

Qualifying Conditions Expanded

The new law adds chronic pain, anxiety disorders, and opioid-use disorder to Georgia's list of qualifying medical conditions. The state's 2015 Low THC Oil Registry previously limited access to patients with 16 specific diagnoses, including intractable seizures, terminal cancer, and Parkinson's disease. Georgia now moves closer to the 38-condition standard common in mature medical programs like Ohio and Pennsylvania.

State health officials estimate the change will make an additional 150,000 Georgia residents eligible for medical cannabis registration. Applications under the expanded criteria open July 1, 2026, through the Georgia Department of Public Health.

New Product Forms Authorized

Patients may now access transdermal patches, suppositories, and topical formulations in addition to low-THC oils. The original statute restricted patients to oil products containing no more than 5% THC by weight. That 5% THC cap remains. But delivery methods now extend beyond oral tinctures and vaporizer cartridges.

Georgia's six Class 1 production licensees—including Trulieve Georgia, Botanical Sciences, and Natures GA—have 90 days to submit product-formulation plans to the Georgia Access to Medical Cannabis Commission. Industry observers expect transdermal patches to reach dispensary shelves by October 2026.

Dispensary Network Unchanged

The law doesn't authorize additional retail licenses or expand the state's current eight-dispensary cap. Georgia operates under a vertically integrated model with six grower-processors each permitted to open one or two retail locations. Seven dispensaries are operational as of June 2026 in Atlanta, Augusta, Macon, Marietta, Savannah, Columbus, and Pooler.

Patient-advocacy groups including Georgia CARE Project criticized the failure to add rural dispensary access. Residents in southwest Georgia still face a drive of more than 120 miles to reach the nearest dispensary in Columbus.

No Changes to THC Limits or Smokable Flower

The 5% THC concentration ceiling remains in place, and smokable flower products are still prohibited. Georgia's medical program continues to restrict patients to low-THC cannabis oil, defined as containing at least equal parts CBD to THC. Since 2019, advocates have pushed unsuccessfully to lift the flower ban and raise potency limits to 15-20% THC, citing patient preference data from neighboring Florida and Arkansas.

Meeting minutes published in May 2026 show the Georgia Access to Medical Cannabis Commission has no current plans to revisit THC caps or flower access.

Implementation Timeline and Next Steps

Key dates for the expanded program:

• July 1, 2026: Patient applications open for new qualifying conditions
• September 9, 2026: Deadline for licensees to submit new product formulations
• October 15, 2026: Estimated shelf date for transdermal and topical products

Updated physician certification forms and patient-registration guidance will be published by the Georgia Department of Public Health by June 25, 2026. For full background on Georgia's medical cannabis framework, see the CannIntel topic hub on Georgia Medical Cannabis Program.